Incidence and risk of endocrine and metabolic abnormalities linked to PARP inhibitors in solid tumors: a meta-analysis
Abstract Background Poly (ADP-ribose) polymerase inhibitors (PARPi) serve as crucial therapeutic agents in solid tumor treatment. Preclinical investigations suggest a potential protective function of PARPi against endocrine and metabolic impairments. Nevertheless, the existing body of evidence remai...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-13579-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571571394314240 |
|---|---|
| author | Shunlian Fu Pingjin Zou Zengyi Fang Xinxiang Zhou Junyang Chen Cuicui Gong Li Quan Bing Lin Qiu Chen Jinyi Lang Meihua Chen |
| author_facet | Shunlian Fu Pingjin Zou Zengyi Fang Xinxiang Zhou Junyang Chen Cuicui Gong Li Quan Bing Lin Qiu Chen Jinyi Lang Meihua Chen |
| author_sort | Shunlian Fu |
| collection | DOAJ |
| description | Abstract Background Poly (ADP-ribose) polymerase inhibitors (PARPi) serve as crucial therapeutic agents in solid tumor treatment. Preclinical investigations suggest a potential protective function of PARPi against endocrine and metabolic impairments. Nevertheless, the existing body of evidence remains inconclusive on this aspect. Purpose Our aim was to evaluate the potential impact of PARPi on endocrine and metabolic disruptions in clinical trials. Data sources We conducted a comprehensive search across the Medline, EMBASE, PubMed, and Web of Science databases, along with the ClinicalTrials.gov registry. Study selection Phase II/III randomized controlled trials (RCTs) investigating the effects of PARPi in metabolic and endocrine processes were selected for inclusion in patients with solid tumors. Data extraction The primary outcomes of interest encompassed metabolic and endocrine dysfunctions. Data synthesis A total of 26 trials (n = 9,590 patients) were included in our meta-analysis. Niraparib demonstrated an increased risk of any-grade hyperglycemia (OR = 2.15, 95% CI 1.28–3.62), with patients receiving PARPi for metastatic pancreatic cancer showing a higher susceptibility to any-grade hyperglycemia (OR = 1.78, 95% CI 1.04–3.04). Conversely, rucaparib exhibited a potential ameliorative effect on hyperglycemia (OR = 0.54, 95% CI 0.30–0.97). No statistically significant disparities were observed for other outcomes associated with PARPi utilization. Limitations Among these RCTs included, 50% were assessed as low qualities due to high risk of bias. Conclusions Our meta-analysis demonstrated that PARPi may exert adverse effects on endocrine and metabolic pathways. Close monitoring of hyperglycemia is recommended for patients undergoing niraparib therapy, especially those with pancreatic cancer. Trial registration This meta-Analysis was prospectively registered in the PROSPERO database with ID CRD42023457959. Graphical Abstract |
| format | Article |
| id | doaj-art-2a57746d41554581b67eeb7d60a3ede4 |
| institution | Kabale University |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-2a57746d41554581b67eeb7d60a3ede42025-02-02T12:28:53ZengBMCBMC Cancer1471-24072025-01-0125111310.1186/s12885-025-13579-1Incidence and risk of endocrine and metabolic abnormalities linked to PARP inhibitors in solid tumors: a meta-analysisShunlian Fu0Pingjin Zou1Zengyi Fang2Xinxiang Zhou3Junyang Chen4Cuicui Gong5Li Quan6Bing Lin7Qiu Chen8Jinyi Lang9Meihua Chen10Chengdu University of Traditional Chinese MedicineDepartment of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of ChinaDepartment of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of ChinaDepartment of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of ChinaChengdu University of Traditional Chinese MedicineChengdu University of Traditional Chinese MedicineChengdu University of Traditional Chinese MedicineHospital of Chengdu University of Traditional Chinese MedicineHospital of Chengdu University of Traditional Chinese MedicineDepartment of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of ChinaDepartment of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of ChinaAbstract Background Poly (ADP-ribose) polymerase inhibitors (PARPi) serve as crucial therapeutic agents in solid tumor treatment. Preclinical investigations suggest a potential protective function of PARPi against endocrine and metabolic impairments. Nevertheless, the existing body of evidence remains inconclusive on this aspect. Purpose Our aim was to evaluate the potential impact of PARPi on endocrine and metabolic disruptions in clinical trials. Data sources We conducted a comprehensive search across the Medline, EMBASE, PubMed, and Web of Science databases, along with the ClinicalTrials.gov registry. Study selection Phase II/III randomized controlled trials (RCTs) investigating the effects of PARPi in metabolic and endocrine processes were selected for inclusion in patients with solid tumors. Data extraction The primary outcomes of interest encompassed metabolic and endocrine dysfunctions. Data synthesis A total of 26 trials (n = 9,590 patients) were included in our meta-analysis. Niraparib demonstrated an increased risk of any-grade hyperglycemia (OR = 2.15, 95% CI 1.28–3.62), with patients receiving PARPi for metastatic pancreatic cancer showing a higher susceptibility to any-grade hyperglycemia (OR = 1.78, 95% CI 1.04–3.04). Conversely, rucaparib exhibited a potential ameliorative effect on hyperglycemia (OR = 0.54, 95% CI 0.30–0.97). No statistically significant disparities were observed for other outcomes associated with PARPi utilization. Limitations Among these RCTs included, 50% were assessed as low qualities due to high risk of bias. Conclusions Our meta-analysis demonstrated that PARPi may exert adverse effects on endocrine and metabolic pathways. Close monitoring of hyperglycemia is recommended for patients undergoing niraparib therapy, especially those with pancreatic cancer. Trial registration This meta-Analysis was prospectively registered in the PROSPERO database with ID CRD42023457959. Graphical Abstracthttps://doi.org/10.1186/s12885-025-13579-1PARP inhibitorsEndocrine and metabolic abnormalitiesMeta-analysis |
| spellingShingle | Shunlian Fu Pingjin Zou Zengyi Fang Xinxiang Zhou Junyang Chen Cuicui Gong Li Quan Bing Lin Qiu Chen Jinyi Lang Meihua Chen Incidence and risk of endocrine and metabolic abnormalities linked to PARP inhibitors in solid tumors: a meta-analysis BMC Cancer PARP inhibitors Endocrine and metabolic abnormalities Meta-analysis |
| title | Incidence and risk of endocrine and metabolic abnormalities linked to PARP inhibitors in solid tumors: a meta-analysis |
| title_full | Incidence and risk of endocrine and metabolic abnormalities linked to PARP inhibitors in solid tumors: a meta-analysis |
| title_fullStr | Incidence and risk of endocrine and metabolic abnormalities linked to PARP inhibitors in solid tumors: a meta-analysis |
| title_full_unstemmed | Incidence and risk of endocrine and metabolic abnormalities linked to PARP inhibitors in solid tumors: a meta-analysis |
| title_short | Incidence and risk of endocrine and metabolic abnormalities linked to PARP inhibitors in solid tumors: a meta-analysis |
| title_sort | incidence and risk of endocrine and metabolic abnormalities linked to parp inhibitors in solid tumors a meta analysis |
| topic | PARP inhibitors Endocrine and metabolic abnormalities Meta-analysis |
| url | https://doi.org/10.1186/s12885-025-13579-1 |
| work_keys_str_mv | AT shunlianfu incidenceandriskofendocrineandmetabolicabnormalitieslinkedtoparpinhibitorsinsolidtumorsametaanalysis AT pingjinzou incidenceandriskofendocrineandmetabolicabnormalitieslinkedtoparpinhibitorsinsolidtumorsametaanalysis AT zengyifang incidenceandriskofendocrineandmetabolicabnormalitieslinkedtoparpinhibitorsinsolidtumorsametaanalysis AT xinxiangzhou incidenceandriskofendocrineandmetabolicabnormalitieslinkedtoparpinhibitorsinsolidtumorsametaanalysis AT junyangchen incidenceandriskofendocrineandmetabolicabnormalitieslinkedtoparpinhibitorsinsolidtumorsametaanalysis AT cuicuigong incidenceandriskofendocrineandmetabolicabnormalitieslinkedtoparpinhibitorsinsolidtumorsametaanalysis AT liquan incidenceandriskofendocrineandmetabolicabnormalitieslinkedtoparpinhibitorsinsolidtumorsametaanalysis AT binglin incidenceandriskofendocrineandmetabolicabnormalitieslinkedtoparpinhibitorsinsolidtumorsametaanalysis AT qiuchen incidenceandriskofendocrineandmetabolicabnormalitieslinkedtoparpinhibitorsinsolidtumorsametaanalysis AT jinyilang incidenceandriskofendocrineandmetabolicabnormalitieslinkedtoparpinhibitorsinsolidtumorsametaanalysis AT meihuachen incidenceandriskofendocrineandmetabolicabnormalitieslinkedtoparpinhibitorsinsolidtumorsametaanalysis |